The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy.
Anatomy of an Epidemic: Psychiatric Drugs and the Astonishing Rise of Mental Illness in America by Robert Whitaker, Ethical Human Psychology and Psychiatry, Volume 7, Number I , Spring 2005 Mon, 29 Aug 2005 Some uncritical promoters of psychiatry and its current biological treatment paradigm have declared that the introduction…
Our criticism of a high risk, speculative drug experiment conducted on healthy children and adolescents at Yale University’s Psychiatric Institute was validated by a federal investigation: and our criticism is now validated by the principle investigator, Dr. Thomas McGlashan.
When the Times refers to an experiment as "bold and controversial" the reporter is sanitizing the fact that the experiment is UNETHICAL—it violates medicine’s cardinal rule "First, do no harm."
APA "Diagnostic Statistical Manual" Task Force has been shown to have financial relationships with drug manufacturers.
“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
Yale engages in fishing expedition in to expand neuroleptic drug market.
Is it ethical to expose healthy children to risks of drug- induced pathology on a speculative, unproven theory?
